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Abstract: Autophagy is a cell-survival pathway with dual role in tumorigenesis, promoting either
tumor survival or tumor death. WNK2 gene, a member of the WNK (with no lysine (K)) subfamily,
acts as a tumor suppressor gene in gliomas, regulating cell migration and invasion; however, its role
in autophagy process is poorly explored. The WNK2-methylated human glioblastoma cell line A172
WT (wild type) was compared to transfected clones A172 EV (empty vector), and A172 WNK2
(WNK2 overexpression) for the evaluation of autophagy using an inhibitor (bafilomycin A1—baf A1)
and an inducer (everolimus) of autophagic flux. Western blot and immunofluorescence approaches
were used to monitor autophagic markers, LC3A/B and SQSTM1/p62. A172 WNK2 cells presented
a significant decrease in LC3B and p62 protein levels, and in LC3A/B ratio when compared with
control cells, after treatment with baf A1 + everolimus, suggesting that WNK2 overexpression inhibits
the autophagic flux in gliomas. The mTOR pathway was also evaluated under the same conditions,
and the observed results suggest that the inhibition of autophagy mediated by WNK2 occurs through
a mTOR-independent pathway. In conclusion, the evaluation of the autophagic process demonstrated
that WNK2 inhibits the autophagic flux in glioblastoma cell line.
Keywords: WNK2; glioblastoma cell line; autophagy; inhibition; autophagic flux
1. Introduction
Gliomas are the most common adult primary brain tumors [1]. Glioblastoma (GBM) is the
highest-grade form of glioma (WHO grade IV), as well as one of the most aggressive types of cancer
with rapid cellular growth, and highly invasive behavior, with a median overall survival time of
15-18 months [2]. The current therapeutic approach is surgery followed by concomitant radiotherapy
and temozolomide-based chemotherapy [3–5]; however, despite significant advances in diagnosis
and therapy in recent decades, the outcomes for high grade gliomas (WHO grade III-IV) remains
unfavorable [6]. To change this scenario, a deeper understanding of glioma cancer biology is needed.
Autophagy is a catabolic mechanism that maintains cellular homeostasis. In this cellular
process proteins or cytoplasmic organelles are sequestered by double-membrane vesicles known
Cells 2020, 9, 485; doi:10.3390/cells9020485 www.mdpi.com/journal/cells
Cells 2020, 9, 485 2 of 12
as autophagosomes [7]. Fusion of autophagosomes with lysosomes forms a structure in which
intracellular degradation occurs, leading to a state of equilibrium of cellular metabolism, as well
as apoptosis [8]. Uncontrolled autophagy is also a cell death mechanism that may occur either in
the absence or concomitantly with signs of apoptosis [9]. The autophagy process has been found
activated in many tumors and its inhibition can lead to both increased cell death and increased survival,
depending on the tissue type, tumor grade, and therapy used [10,11]. Furthermore, it is known that
prolonged and progressive autophagy stress can lead to cell death [12]. Thus, induction of autophagic
cell death has been proposed as a possible mechanism of tumor suppression [13]. Since autophagy can
be viewed as pro- or anti-tumor, depending on the context [14], the dissection of its role in gliomas, as
well as the associated molecular mechanisms is of critical importance. This is particularly relevant
because glioma cells usually respond to therapeutic agents that induce the autophagic process such as,
TMZ and rapamycin in a clinical setting [15].
The serine/threonine kinase WNK2 (with no lysine protein kinase 2) acts as a tumor suppressor
in GBM and is associated to carcinogenesis-related pathways [16–18]. WNK2 inhibits cell
proliferation, invasion, and migration [19–21]. These effects are lost following epigenetic silencing by
hypermethylation of WNK2 promoter region [16,17]. However, the role of WNK2 in cell death is still
unclear and contradictory data concerning WNK2 as an autophagic modulator has been reported [22,23].
Therefore, the present study aimed to explore the in vitro role of WNK2 in autophagic process in gliomas.
2. Materials and Methods
2.1. Cell Lines and Cell Culture
The human glioblastoma cell lines A172 WT (wild-type), A172 EV (empty-vector), and A172
WNK2 (WNK2 overexpression) (Supplementary Figure S1) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis,
MO, USA), 1% p/s (penicillin/streptomycin) (Life Technologies, Carlsbad, CA, USA) at 37 ◦C under
humidified atmosphere containing 5% CO2. A172 EV and A172 WNK2 were generated and maintained
as previously described [18]. The authentication of the cell lines was performed by a DNA short
tandem repeat (STR) profile at the Diagnostic Laboratory at Barretos Cancer Hospital (São Paulo,
Brazil), as previously described [24].
2.2. Cell Treatment
The A172 WT, A172 EV, and A172 WNK2 cell lines were plated in 6-well plates at a density of
6 × 105 cells/well, and allowed to adhere overnight. After this period, the cells were starved for 3 h
with DMEM 0.5% FBS. Next, for the control cells, the growth medium was replaced with DMEM 10%
FBS. To evaluate the autophagic process, the cells were treated with Earle’s Balanced Salt Solution
(EBSS) (Thermo Fisher Scientific, Waltham, MA, USA). To evaluate the autophagy process, 20 nM
bafilomycin A1 (baf A1) (Sigma-Aldrich) was added to the EBSS. Furthermore, 10 nM everolimus
(Sigma-Aldrich) was added, acting on the inhibition of mammalian target of rapamycin (mTOR),
resulting in the induction of autophagy. Cells were incubated with the respective treatments for 4 and
6 h.
2.3. Immunofluorescence
Cells were plated in a 24-well plate at a density of 7.5 × 105 cells/well, and allowed to adhere for
at least 24 h. Subsequently, the cells were starved for 3 h with DMEM (0.5% FBS) before treatment,
and then treated with 30 µM chloroquine (CQ) (Molecular Probes, Invitrogen, Eugene, OR, USA)
for 16 h. Next, the cells were incubated with formaldehyde 3.7% in Dulbecco’s phosphate-buffered
saline (DPBS 1X) (Sigma-Aldrich) and permeabilized with 0.2% Triton X-100 in DBPS 1X for 15 min at
room temperature. The cells were incubated for 2 h with a primary LC3 rabbit polyclonal antibody
(Molecular Probes, Invitrogen, Eugene, OR, USA) diluted in DPBS with 5% BSA (Bovine Serum
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Albumin), followed by the secondary antibody Alexa Fluor 488 (Life Technologies, Carlsbad, CA,
USA) for 1 h at room temperature. Finally, the cells were labeled with HOECHST 33342 (1:2000) (Life
Technologies) and phalloidin-rhodamine (1:200) (Molecular Probes, Invitrogen, Eugene, OR, USA).
Images were acquired by the High Content In Cell Analyzer 2200 platform (GE Healthcare Life Sciences,
Chicago, IL, USA) and quantification was performed in the Image-Pro software (Media Cybernetics,
Rockville, MD, USA).
2.4. Transient Transfection
The pDest-mCherry-EGFP-LC3B and pDest-mCherry-GFP-p62 plasmids were kindly provided
by Prof. Terje Johansen (Molecular Cancer Research group, Institute of Medical Biology, University of
Tromsø, Tromsø, Norway) for transient transfection. Cells were plated in 6-well plates at a density
of 2.5 × 105 cells/well 24 h before transfection with plasmid using the Lipofectamine 3000 reagent
(Invitrogen) according to the manufacturer’s recommendations. After 5 h, the transfection medium
was replaced by a fresh culture medium, and the cells were incubated for another 24 h. Subsequently,
the cells were starved with Hank’s Balanced Salt solution (HBSS) (Invitrogen) for 4 h prior to treatment
with 200 µM baf A1 (Sigma Aldrich) for 24 h. After this period, the cells were labeled with HOECHST
(1:2000) (Life Technologies). Images were acquired by the High Content In Cell Analyzer 2200
platform (GE Healthcare Life Sciences) and quantification was performed in the Image-Pro software
(Media Cybernetics).
2.5. Western Blotting Analysis
Total protein from cell death and autophagy assays was analyzed by western blot as previously
described [25]. The following antibodies were used: Anti-LC3A/B (1:1000), anti-SQSTM1/p62 (1:1000),
anti-p-p70S6K (Thr389) (1:1000), anti-p-4EBP1 (1:1000), anti-p-mTOR (Ser2448) (1:1000), α-tubulin
(1:2000), and β-actin (1:2000), all purchased from Cell Signaling (Danvers, MA, USA). β-actin and
α-tubulin were used as a loading control. HRP-conjugated goat anti-mouse and goat anti-rabbit (all from
Cell Signaling) were used as secondary antibodies. Chemiluminescence using ECL (GE Healthcare Life
Sciences) was detected on an Image Quant LAS4000 mini photo documentation system (GE Healthcare
Life Sciences). The subsequent quantification was performed by Image J software version 1.52s
(National Institutes of Health—https://imagej.nih.gov/ij/).
2.6. Statistical Analysis
Data from experiments were expressed as the mean± standard deviation (SD) of three independent
experiments. p-values were calculated by two-way ANOVA. Symbols indicate statistical comparisons
(* p < 0.05, ** p < 0.01, *** p < 0.001). The aforementioned analysis was performed using GraphPad
PRISM version 5 (GraphPad Software, San Diego, CA, USA).
3. Results
WNK2 Inhibits Autophagic Flux
To investigate the potential effect of WNK2 overexpression on autophagy, the A172-derived cell
lines (A172 WT, A172 EV, and A172 WNK2) were evaluated for the main markers recommended by
the guidelines for the use and interpretation of assays for autophagy monitoring (3rd edition) [26].
The cells were treated with baf A1 as an autophagy flux inhibitor, as well as with starvation (EBSS) and
everolimus as autophagy inducers. The western blot analysis demonstrated that WNK2 overexpression
significantly decreased LC3B (microtubule-associated protein 1 light chain 3 beta) protein lipidation,
and SQSTM1 (sequestosome 1)/p62 levels after 4 and 6 h of combinatorial treatments (Figure 1A,B)
indicating a clear autophagic flux inhibition.
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Figure 1. Evaluation of LC3B and p62 proteins by western blot. A172 WT, A172 EV, and A172 WNK2 
cell lines were treated with bafilomycin A1 (BAF, 20 nM), starvation (EBSS medium), everolimus 
(EVERO, 10 nM), or the combination BAF+EVERO for 4 (A) or 6 h (B). The graphs are representative 
of three independent biological experiments. β-actin protein was used as an endogenous loading 
control. Symbols mean (*) p < 0.05; (**) p < 0.01; (***) p < 0.001. 
Since everolimus, an mTOR pathway inhibitor, was used in combination with baf A1 treatment, 
proteins belonging to this pathway were evaluated. Interestingly, under these conditions, the activity 
of mTOR or the phosphorylation of its substrates EBP1 and p70S6K did not differ between the WNK2-
overexpressing cell line compared to the WT and EV controls (Figure 2A,B), suggesting that the 
observed autophagic flux inhibition in the WNK2 presence is mTOR-independent. 
To confirm the autophagy flux inhibition observed in the WNK2 overexpressing cells, we 
transfected the three A172-derived cell lines with tandem conjugated pDest.mCherry-GFP-p62 and 
pDest.mCherry-GFP-LC3B plasmids [27] and then treated for autophagy induction with HBSS and 
with the autophagy flux inhibitor baf A1. In this approach, yellow signal indicates the presence of 
LC3B or p62 in autophagosomes, whereas red signal indicates autophagolysosomes due to loss of 
green fluorescence in their acidic environment. We found a marked decrease in p62-positive puncta 
in A172 WNK2 cells in the HBSS + baf A1 treated condition (Figure 3A). On the other hand, these 
cells showed no change in autophagic flux as evidenced by the number of LC3B-positive puncta when 
compared to control cells; however, a decrease in red dots representing autophagolysosomes was 
evidenced between WT and WNK2 cell line (Figure 3B). 
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Since everoli us, an T R path ay inhibitor, as used in co bination ith baf 1 treat ent,
proteins belonging to this path ay ere evaluated. Interestingly, under these conditions, the activity
of T or the phosphorylation of its substrates EBP1 and p70S6K did not differ between the
WNK2-overexpressing cell line compared to the WT and EV controls (Figure 2A,B), suggesting that the
observed autophagic flux inhibition in the NK2 presence is mTOR-independent.
To confirm the autophagy flux inhibition observed in the WNK2 overexpressing cells, e
transfected the three A172-derived cell lines with tandem conjugated pDest.mCherry-GFP-p62 and
p est. herry- FP-L 3B plas ids [27] and then treated for autophagy induction ith BSS and
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co are to control cells; ho ever, a decrease in red dots representing autophagolysoso es as
evidenced bet een T and NK2 cell line (Figure 3B).
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Figure 2. Evaluation of proteins involved in mammalian target of rapamycin (mTOR) pathway
by western blot. A172 WT, A172 EV, and A172 WNK2 cell lines were treated with bafilomycin
A1 (BAF, 20 nM), starvation (EBSS medium), or everolimus (EVERO, 10 nM) for 4 (A) and 6 h (B).
The protein extract was evaluated for phosphorylation of mTOR and its substrates p-p70S6K and
p-4EBP1 by western blot. Normalized densitometric band intensities of mTOR activity used α-tubulin
as an endogenous loading control. For the substrates p-p70S6K and p-4EBP1, β-actin was used as
a endogenous co trol. The graphs are representative of two independent biological experiments.
n.s.: Not significant.
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Figure 3. Evaluation of LC3B and p62 proteins by using transient transfection with pDest.mCherry-
GFP-LC3B and pDest.mCherry-GFP-p62 plasmids. A172 WT, A172 EV, and A172 WNK2 cell lines 
were transfected with plasmid pDest.mCherry-GFP-LC3B (A) or pDest.mCherry-GFP-p62 (B) and 
then treated for 24 h with bafilomycin A1 (baf A1). Hoechst (DAPI) treatment indicates nuclear 
staining by blue fluorescence. FITC indicates green fluorescence and Texas Red indicates red 
fluorescence wavelengths by the In Cell Analyzer platform. In the figures, yellow dots indicate the 
presence of LC3B or p62 in autophagosomes, whereas red dots indicate autophagolysosomes due to 
loss of green fluorescence in an acidic environment. In the graphics, the yellow and red bars indicate 
the quantification of autophagossomos and autophagolysosomes, respectively, observed in the 
merged. The graphs are representative of two independent biological experiments. Images were 
quantified using Image-Pro software. Symbols mean (*) p < 0.05; (**) p < 0.01; (***) p < 0.001. (+) means 
presence of baf A1; (-) means absence of baf A1.  
Additionally, another approach was used for evaluating autophagic flux in the edited cell lines. 
In these results, WNK2 overexpression changed LC3B levels after 16 h upon another autophagy 
inhibitor treatment, chloroquine at 30 µM (Figure 4A,B) when compared with WT cell line. 
Figure 3. Evaluation of LC3B and p62 proteins by using transient transfection with
pDest.mCherry-GFP-LC3B and pDest.mCherry-GFP-p62 plasmids. A172 WT, A172 EV, and A172 WNK2
cell lines were transfected with plasmid pDest.mCherry-GFP-LC3B (A) or pDest.mCherry-GFP-p62
(B) and then treated for 24 h with bafilomycin A1 (baf A1). Hoechst (DAPI) treatment indicates
nuclear staining by blue fluorescence. FITC indicates green fluorescence and Texas Red indicates red
fluorescence wavelengths by the In Cell Analyzer platform. In the figures, yellow dots indicate the
presence of LC3B or p62 in autophagosomes, whereas red dots indicate autophagolysosomes due to
loss of green fluorescence in an acidic environment. In the graphics, the yellow and red bars indicate
the quantification of autophagossomos and autophagolysosomes, respectively, observed in the merged.
The graphs are representative of two independent biological experiments. Images were quantified
using Image-Pro software. Symbols mean (*) p < 0.05; (**) p < 0.01; (***) p < 0.001. (+) means presence
of baf A1; (-) means absence of baf A1.
Additionally, another approach was used for evaluating autophagic flux in the edited cell lines.
In these results, WNK2 overexpression changed LC3B levels after 16 h upon another autophagy
inhibitor treatment, chloroquine at 30 µM (Figure 4A,B) when compared with WT cell line.
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platform. (B) Graph of the quantification of LC3B vesicles in merged after control condition and 
treatment with CQ for 16 h. The graphs are representative of three independent biological 
experiments. The quantification of images was realized in Image-Pro software. Symbols mean (*) p < 
0.05; (**) p < 0.01; (***) p < 0.001. 
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degradation and direct them to the lysosome. Generally, p62 levels correlate inversely with 
autophagic activity. However, it is unclear whether p62 is degraded only by autophagy or partially 
by the ubiquitin-proteasome pathway [28]. Thus, p62, as well as LC3, can be transcriptionally 
regulated during autophagy [29].Western blot analysis showed a significant decrease in the levels of 
LC3B and p62 markers after 4 and 6 h of baf A1 treatment and everolimus. In addition, 
immunofluorescence results demonstrated a decrease in LC3B level after CQ treatment and p62 
puncta after HBSS + baf A1 treatment and although no statistical difference was found in the LC3B 
puncta, there was a decrease in red dots in the overexpressing WNK2 cell line when compared to the 
WT cell line. Previous studies point to WNK2 acting in the early stages of autophagic flux, however, 
with contradictory functions. Szyniarowski et al. (2011) [23] silenced WNK2 via siRNA (small 
Figure 4. Evaluation of the effect of WNK2 overexpression on the autophagic process after chloroquine
(CQ) treatment. (A) A172 WT, A172 EV, and A172 WNK2 cell lines were treated with DMEM 0.5%
FBS for control conditions and to induce autophagy with the autophagy flux inhibitor chloroquine
(CQ, 30 µM) for 16 h after a 3-h starvation period. Images were acquired at DAPI (blue, nuclei),
FITC (green, LC3 dots), and CY3 (red, cytoplasm) wavelengths by the In Cell Analyzer platform.
(B) Graph of the quantification of LC3B vesicles in merged after control condition and treatment with CQ
for 16 h. The graphs are representative of three independent biological experiments. The quantification
of images was realized in Image-Pro software. Symbols mean (*) p < 0.05; (**) p < 0.01; (***) p < 0.001.
4. Discussion
The role of WNK2 in the autophagy process is still contradictory. In this study, the assessment of
the autophagic process using different methodological approaches has suggested that the presence of
WNK2 inhibits the autophagic flux in glioma cell lines and it is independent of the mTOR pathway.
In the autophagic process, some important markers allow to estimate autophagic activity, such as
LC3 and p62. Typically, LC3A is converted to LC3B by lipidation and is present in the formation of
autophagosomes [26]. p62 protein binds to ubiquitinylated proteins, that are labeled for degradation and
direct them to the lysosome. Generally, p62 levels correlate inversely with autophagic activity. However,
it is unclear whether p62 is degraded only by autophagy or partially by the ubiquitin-proteasome
pathway [28]. Thus, p62, as well as LC3, can be transcriptionally regulated during autophagy [29].
Western blot analysis showed a significant decrease in the levels of LC3B and p62 markers after 4
and 6 h of baf A1 treatment and everolimus. In addition, immunofluorescence results demonstrated
a decrease in LC3B level after CQ treatment and p62 puncta after HBSS + baf A1 treatment and
although no statistical difference was found in the LC3B puncta, there was a decrease in red dots in the
overexpressing WNK2 cell line when compared to the WT cell line. Previous studies point to WNK2
acting in the early stages of autophagic flux, however, with contradictory functions. Szyniarowski et al.
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(2011) [23] silenced WNK2 via siRNA (small interfering RNA) in MCF-7 human breast carcinoma cells
and reported p62 accumulation, thus inhibiting autophagic flux [30]. Accumulation of this protein
indicates defective maturation of autophagosomes [23], thus WNK2 would act as a positive regulator
of the autophagic process. On the other hand, Guo et al. (2015) silenced WNK2 through shRNAs (short
hairpin RNA) that induced a significant increase in LC3B by immunofluorescence [22] demonstrating
that WNK2 could inhibit autophagy flux. It is noteworthy that according to Yoshii et al. (2017),
cells that present a low number of positive puncta in the basal condition, as we reported, and that do
not suffer alterations after treatment with baf A1 are suggestive of defects in the autophagy induction
process [31].
It is known that one of the major biological changes in glioma is the alteration of the PI3K
(phosphatidyl inositol 3 kinase)/AKT/mTOR pathway [32]. Inhibition of mTOR may be detected as
dephosphorylation of its substrates p70S6K kinase and 4EBP1 (4E binding protein 1) [33] and are
correlated with the autophagic process in gliomas [34,35]. To assess the impact of this pathway, we used
treatment with the autophagic inducer (everolimus), a rapamycin analog that inhibits mTOR signaling in
combination with an autophagic inhibitor (baf A1). The results suggest that WNK2-mediated autophagy
inhibition occurs independently of the mTOR pathway. Previous studies relating WNK2 and autophagy
have also contradicted the effect of this gene on mTOR activity. While Szyniarowski et al. (2011) did not
find any effect on mTORC1 activity in breast cancer cell lines by analyzing the phosphorylation status
its p70S6K [23], another study using chronic myeloid leukemia demonstrated suppressed autophagy
by activating mTOR [22]. Furthermore, it was recently reported that mTOR mutations have essential
implication in inducing resistance to the mTOR inhibitors preserving its activity [36], as observed in
our study. One hypothesis for our findings would be that WNK2 could promote defects in the initial
autophagy flux or autophagosome maturation [22,23]. During autophagosome formation PI3K activity,
an upstream element in the mTOR pathway, is required and when suppressed inhibits autophagic
flux. In this sense, the mechanism used by WNK2 to inhibit autophagic flux would be similar to the
3-methyladedine autophagy inhibitor (3-MA) [36].
TMZ is considered the most effective treatment drug for GBMs and its main mechanism of
action is on autophagy [37,38]. However, depending on the cellular context, it has been shown that
autophagy could lead to the development of resistance to TMZ treatment rather than cell death [39–41].
Recently, therapeutic molecules that inhibit autophagy such as CQ and hydroxychloroquine have
been used in phase I/II clinical trials concomitant with TMZ treatment and radiation and have shown
increased survival in patients diagnosed with GBM [15,42]. In this study, assessment of the autophagic
process has suggested that the presence of WNK2 inhibits the autophagic flux in glioblastoma cell line.
It will now be interesting to study the role of WNK2 in autophagic vesicular trafficking in response
to therapy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/2/485/s1,
Figure S1: Validation of WNK2 overexpression by RT-PCR.
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